Histology
Non-Small Cell Adenocarcinoma
CI-CAN-00003439Explore in graph →
53 active trials127 evidence items
- NCIt
- C27745
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00003439Explore in graph →
Clinical trials
236 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 |
| clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04533451 | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 101 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06477211 | DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma | completed | — | 292 | Nanjing UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07002788 | Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery. | active not recruiting | N/A | 122 | Hacettepe UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT06953492 | Sleep State in Lung Cancer: A Retrospective Analysis | completed | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 689 | CelltrionINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06818955 | Orlistat Overcoming Third-generation EGFR-TKI Resistance(OOTER) | not yet recruiting | Phase 2 | 36 | Ping PengOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | terminated | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT04588064 | 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma | completed | N/A | 63 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT01014286 | Lung Cancer Mutation Consortium Protocol | completed | — | 1,100 | University of Colorado, DenverOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06745830 | Lymph Node Pathologic Grading Strategy | recruiting | — | 2,998 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06730477 | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma | enrolling by invitation | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05925764 | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma | recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645743 | Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma | not yet recruiting | — | 1,100 | The Third Affiliated Hospital of Kunming Medical College.OTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06215885 | Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules | unknown | — | 220 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05830812 | Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602661 | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy | not yet recruiting | Phase 1 | 65 | Surrey Thoracic Surgery GroupOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05794698 | Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) | completed | — | 827 | Fudan UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04740047 | Cios Mobile 3D Spin for Robotic Bronchoscopy | completed | — | 38 | Mayo ClinicOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06441357 | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter | unknown | — | 2,000 | Tang-Du HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK(BEYOND) | recruiting | Phase 2 | 78 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05982574 | Tumor Microenvironment | active not recruiting | — | 300 | University Hospital HeidelbergOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Dec 9, 2025source: clinicaltrials